Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become...

Descripción completa

Detalles Bibliográficos
Autores principales: Lieverse, Relinde I. Y., Van Limbergen, Evert J., Oberije, Cary J. G., Troost, Esther G. C., Hadrup, Sine R., Dingemans, Anne-Marie C., Hendriks, Lizza E. L., Eckert, Franziska, Hiley, Crispin, Dooms, Christophe, Lievens, Yolande, de Jong, Monique C., Bussink, Johan, Geets, Xavier, Valentini, Vincenzo, Elia, Giuliano, Neri, Dario, Billiet, Charlotte, Abdollahi, Amir, Pasquier, David, Boisselier, Pierre, Yaromina, Ala, De Ruysscher, Dirk, Dubois, Ludwig J., Lambin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296663/
https://www.ncbi.nlm.nih.gov/pubmed/32539805
http://dx.doi.org/10.1186/s12885-020-07055-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296663/
https://www.ncbi.nlm.nih.gov/pubmed/32539805
http://dx.doi.org/10.1186/s12885-020-07055-1

Ejemplares similares